

**Why does Chiasma expect the MYCAPSSA commercial launch will be a differentiated rare disease launch?**

Chiasma expects the launch of MYCAPSSA will be have a differentiated rare disease launch in the U.S. for a few reasons. First, patients currently on octreotide or lanreotide injectable therapies are in general readily identifiable and are managed by a small number of endocrinologists; second, octreotide, the active agent in MYCAPSSA, is widely used and physicians have become very comfortable with it over the years; third, there is already a well-informed and active patient community; and lastly, given the current COVID-19 environment, Chiasma believes patients will increasingly prefer products that are not administered in physician's offices, and, like MYCAPSSA, can be taken orally at home.

Dated: June 26, 2020